Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Med Pediatr Oncol. 2002 Aug;39(2):86-92.

Cardiac status in bone tumor survivors up to nearly 19 years after treatment with doxorubicin: a longitudinal study.

Author information

  • 1Department of Pediatrics, Division of Pediatric Oncology/Hematology, University of Groningen/University Hospital, Groningen, The Netherlands. a.postma@bkk.azg.nl

Abstract

BACKGROUND:

Longitudinal assessment of cardiac toxicity in anthracycline-treated long-term bone tumor survivors.

PROCEDURES:

Cardiac status was assessed in 29 patients 14.1 (range 7-18.7) years after treatment with doxorubicin (DOXO) 360 mg/m(2) (median 225-550). The median age of the patients at the time of the study was 32.5 years (range 19.7-52). The evaluation consisted of an electrocardiogram (ECG), 24-hr ambulatory ECG with analysis of heart rate variability (HRV) and echocardiography. The results were compared to those of a study of the same patients that was performed 5 years earlier 8.9 years (range 2.3-14.1) after treatment. [Postma et al.: Med Pediatr Oncol 26:230-237, 1996]

RESULTS:

We found no progression of ECG abnormalities, arrhythmias, or echocardiographic abnormalities. Females were at risk for reduced contractility (P = 0.006). HRV was significantly reduced compared to age- and sex-matched controls and compared to the previous results.

CONCLUSIONS:

Anthracycline-related late echocardiographic abnormalities and arrhythmias detected 8.9 years after treatment, showed no further deterioration with ongoing follow-up. However, there was a significant reduction of HRV. This suggests that HRV might be a sensitive test for detection of anthracycline-induced cardiac toxicity.

Copyright 2002 Wiley-Liss, Inc.

PMID:
12116055
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk